Retron is a biotechnology company with a diverse portfolio focused on cutting-edge advancements in the life sciences sector. The company operates in the biotech market, serving clients ranging from research institutions to pharmaceutical companies. Retron's business model revolves around developing and commercializing innovative solutions in DNA synthesis, cell engineering, and therapeutic development. Ansa Biotechnologies, a part of Retron's portfolio, specializes in enzymatic DNA synthesis, offering precise and efficient solutions for genetic research. Portal Bio focuses on next-generation cell engineering, utilizing mechanical delivery systems to enhance cellular functions. Radar Therapeutics is dedicated to precision mRNA-based therapeutics, employing ADARs for targeted gene editing. Siren Biotechnologies works on universal AAV immuno gene therapy for cancer, aiming to revolutionize cancer treatment. TwoStep Therapeutics provides PIP delivery systems for targeting solid tumors, enhancing the efficacy of cancer therapies. Glyphic Biotechnologies is at the forefront of next-gen protein sequencing, providing detailed insights into protein structures. Extropic AI explores thermodynamic computing, pushing the boundaries of computational biology. Juvena Therapeutics focuses on regeneration through secreted protein therapeutics, offering potential breakthroughs in regenerative medicine. Retron generates revenue through partnerships, licensing agreements, and the commercialization of its proprietary technologies.
Keywords: biotechnology, DNA synthesis, cell engineering, mRNA therapeutics, protein sequencing, gene therapy, cancer treatment, regenerative medicine, computational biology, licensing.